UFC GYM® Unveils Powerful Franchise Opportunity with UFC GYM Jiu-Jitsu
LAS VEGAS, June 2, 2025 /PRNewswire/ — UFC GYM®, the groundbreaking extension of UFC®, is introducing its newest franchise offering: UFC GYM Jiu-Jitsu. This signature studio model, featuring nearly 2,500 square feet of space dedicated to practicing one of mixed martial arts' most popular practices, is designed to deliver world-class Jiu-Jitsu instruction, integrated MMA-inspired programming and a strong community culture – making it an exciting business opportunity for passionate martial artists and entrepreneurs alike.
Photos available to download here, courtesy of UFC GYM®
Designed with simplicity and scalability in mind, UFC GYM Jiu-Jitsu offers a turnkey franchise model backed by the global power and credibility of the UFC GYM brand. Studios will be led by qualified Jiu-Jitsu practitioners, with instruction provided by experienced coaches, including certified black belts and higher. The model offers an ideal opportunity for black belts who are passionate about teaching but prefer to avoid the complexities of running a business. It's a path to ownership, professional growth and meaningful impact in a rapidly expanding market.
This bold new concept will combine the dynamic discipline with UFC GYM's elite programming, delivering the benefits of MMA in a way that's more accessible to the broader fitness community, while also offering entrepreneurs a proven, high-growth business model backed by one of the most powerful brands in sports. UFC GYM's programming has been developed by top leaders in the discipline, who are certified through a rigorous process, assuring the best guidance in the industry. Members can experience MMA training in an environment that's comfortable for all levels, with programs available for youth and adults, from first-timers to competitive athletes.
For those who desire competition, UFC GYM Jiu-Jitsu will provide access to Alta Global Group's Warrior Training Program, a structured fight-camp-style program that empowers everyday athletes to train like fighters, with the potential to step into the Octagon. Throughout the studios, UFC GYM Jiu-Jitsu will provide unified programming and belt testing developed by elite leaders in the discipline, ensuring consistency in instruction, testing and more. From black belts to professional strikers and mixed martial artists, only UFC GYM provides an all-in-one experience.
'With 2.8 million active practitioners in the U.S. alone, Jiu-Jitsu's popularity continues to surge as more people seek self-defense skills and dynamic fitness training,' said Adam Sedlack, CEO of UFC GYM. 'UFC GYM Jiu-Jitsu delivers an authentic, world-class training experience, backed by UFC's unmatched credibility and brand strength.'
To support franchisees, UFC GYM is partnering with BJJ Link, a premier gym management and engagement platform, to enhance the operational efficiency and community connectivity of its new UFC GYM Jiu-Jitsu studios. BJJ Link provides a full suite of tools for gym operations, student engagement and content monetization, serving more than 50,000 active students and expanding MMA.INC's reach to 18,000 gyms worldwide. The platform seamlessly integrates gym management, payment processing and social connectivity tools, optimizing engagement and revenue generation for gym owners. This collaboration reinforces MMA.INC's mission to unify and modernize the martial arts industry while positioning UFC GYM Jiu-Jitsu as a cutting-edge player in the combat sports ecosystem.
UFC GYM models, including UFC GYM, UFC FIT and Class UFC GYM, now range from 1,500 to more than 85,000 square feet with the addition of the UFC GYM Jiu-Jitsu, and are thoughtfully designed to give members the tools they need to embrace their fighting spirit and achieve their fitness goals. For those inspired by UFC GYM's growth and vision, opportunities to become a part of the brand through ownership are available. With locations already being developed across continents, joining the UFC GYM franchise provides entrepreneurs with the chance to be part of a global leader in the fitness industry. For franchising information, visit www.ufcgymfranchise.com or contact franchiseinfo@ufcgym.com. For more information and a list of locations, please visit www.ufcgym.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
an hour ago
- The Star
Private doctors file lawsuit against government over medicine price display regulation
PETALING JAYA: Doctors from the private sector are suing the government over the rule governing the display of medicine prices. This comes after several private practitioners filed for judicial review on July 24 against the government in the Kuala Lumpur High Court. The application was filed on Tuesday (July 29) by the Association of Private Practitioners, Sabah (APPS), the Malaysian Medical Association (MMA), the Malaysian Association for the Advancement of Functional and Interdisciplinary Medicine (Maafim), the Organisation of Malaysian Muslim Doctors (Perdim), the Federation of Private Medical Practitioners Associations Malaysia (FPMPAM), the Malaysian Private Dental Practitioners' Association (MPDPA), the Society of Private Medical Practitioners Sarawak (SPMPS) and one Dr Saifulbahri Ahmad. The lawsuit was in relation to the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025, which came into effect on May 1. The Domestic Trade and Cost of Living Minister, the Health Minister and the government of Malaysia were named as the first, second and third respondents respectively. The medical practitioners are seeking an order of certiorari to quash the Domestic Trade and Cost of Living Ministry's Price Control and Anti-Profiteering (Price Making for Drug) Order 2025, which is also the impugned order in this case. As part of the relief, they are also seeking a declaration that the impugned order is void as it is 'tainted with illegality, irrationality and unreasonableness, disproportionality and impropriety.' 'The enforcement of the Impugned Order, insofar as its application to private healthcare facilities and/or registered medical practitioners and dentists, be stayed until full disposal of the Applicants' application for judicial review,' read the statement of the claim of the case. Among the grounds for judicial review is the government's failure to recognise the difference between drugs sold by retail and those administered for treatment. It also added that the Domestic Trade and Cost of Living Minister had breached principles of natural justice by arriving at the decision without consulting registered medical practitioners represented by the MMA. They said that while the purpose of the regulation was to curb profiteering activities, it has created unwarranted competition among drug providers, with the sole focus being the price of drugs. 'This means even small-scale community clinics operated by general practitioners (GPs) and specialists have to now compete with large-scale drug retailers, for example, international chain pharmacies who already enjoy a larger market control and the ability to gain further control of retail customers by selling drugs at a much lower price,' they said adding that small scale community clinics would be at a disadvantage if forced to enter into an unwarranted competition with large-scale pharmaceutical companies. They said that drug prices in clinics are determined by variables such as manufacturers, freight charges, import or export duties, importers, distributors, volume purchased, the location of the clinics, different formulations of the same product, provisions for wastage of expired or unused drugs and staff and administrative expenses. The price display rule that came into effect on May 1 was met with much resistance by private healthcare practitioners. A three-month grace period has also been given, where no compounds would be issued and the government would instead focus on advocacy and education. The case management has been set for Aug 22.
Malaysian Reserve
21 hours ago
- Malaysian Reserve
C2FO Recognized Among CNBC's World's Top Fintech Companies 2025
KANSAS CITY, Mo., July 28, 2025 /PRNewswire/ — C2FO is pleased to announce its recognition in the third edition of CNBC's World's Top Fintech Companies 2025. Presented by CNBC and Statista Inc., this award highlights the most innovative and impactful companies in the fintech sector. The awards list was unveiled on July 16 and is available on the CNBC website. The selection process involved a comprehensive analysis of thousands of firms' quantitative key performance indicators, growth metrics and industry influence, with data sourced from public reports, company submissions and independent research to determine top contenders in the payments, neobanking, alternative financing, wealth technology, digital assets, enterprise fintech and insurtech categories. C2FO is honored to be recognized in the alternative financing category, reflecting its commitment to transforming the financing landscape. The C2FO platform allows companies to easily accelerate invoice payments from their customers without the barriers of traditional lending and risk-based underwriting. To date, C2FO has funded over $400 billion in on-demand working capital to more than 100,000 businesses worldwide. 'Earning a spot on CNBC's World's Top Fintech Companies is a great accomplishment by our team,' said Alexander 'Sandy' Kemper, founder and CEO of C2FO. 'As we approach our near-term milestone of $500 billion in funding for our customers, we are acutely aware of everything that has to be done to meet the global need for more working capital to power economic growth and job creation.' This award highlights C2FO's position as a leader in finance solutions and a trusted partner among the world's top enterprises. C2FO continues to bring businesses together through its global network powered by comprehensive industry analytics and cutting-edge AI technology to drive working capital growth for its customers. For more information about the award and to read the complete list, please visit CNBC's website here. About C2FOC2FO is the world's on-demand working capital platform, providing businesses with fast, flexible and equitable access to low-cost capital. C2FO enables trust and transparency in working capital finance through its suite of solutions using patented Name Your Rate® technology that enables companies to be paid sooner by the world's largest enterprises. Currently serving hundreds of thousands of business customers globally, the platform has delivered more than $400 billion in risk-free capital since its inception. Founded in 2008 and headquartered in Kansas City, USA, with offices around the globe, C2FO's mission is to ensure every business has the capital needed to thrive. To learn more, visit Media Contact:Carrie Bratcherpr@
Malaysian Reserve
a day ago
- Malaysian Reserve
HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, July 28, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the 'Class Period'), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers' top executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Hims & Hers class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.' The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk'; and (ii) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated. The Hims & Hers class action lawsuit further alleges that on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.' On this news, the price of Hims & Hers stock fell more than 34%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims & Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims & Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims & Hers class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims & Hers class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
